Adial Pharmaceuticals, Inc. (ADIL) Stock Score, Valuation & Financial Research

Adial Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ADIL

Adial Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 3.98. These figures are a research snapshot, not a buy or sell recommendation.

What Adial Pharmaceuticals, Inc. does

Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of therapeutic agents, specifically its lead investigational drug candidate AD04, with the objective of achieving regulatory approval and subsequent commercialization through licensing or direct market entry.

Products and services

  • The company's primary product candidate is AD04, a serotonin-3 receptor antagonist currently in clinical development for the treatment of Alcohol Use Disorder (AUD).

Customer types

Healthcare providers and patients (potential future market).

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company utilizes various third-party contract research organizations to manage and conduct its clinical trials, including the ONWARD trial. Source

Business strengths to evaluate

  • Clinical development program for AD04 targeting Alcohol Use Disorder Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing Source
  • Uncertainty regarding regulatory approval for drug candidates Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ADIL financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.98
Market capitalization:
10.45M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -57.8M
Free cash flow:
USD -6.49M
Cash:
USD 28.71M
Total debt:
USD 0.00
EPS:
USD -16.53

What stands out

  • Free cash flow is USD -6.49M, negative for the stored period.
  • The balance sheet shows USD 28.71M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 28.71M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ADIL

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ADIL fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ADIL likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ADIL to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of ADIL's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research ADIL

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.